Valeant Pharmaceuticals Intl Inc  

(Public, NYSE:VRX)   Watch this stock  
Find more results for NYSE:BVF
83.44
-2.52 (-2.93%)
After Hours: 83.20 -0.24 (-0.29%)
Feb 11, 7:35PM EST  
NYSE real-time data - Disclaimer
Currency in USD
Range 79.62 - 85.13
52 week 69.33 - 263.81
Open 83.76
Vol / Avg. 7.13M/6.89M
Mkt cap 28.15B
P/E 47.23
Div/yield     -
EPS 1.77
Shares 341.19M
Beta 0.71
Inst. own 58%
Feb 22, 2016
Q4 2015 Valeant Pharmaceuticals International Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Jan 13, 2016
Valeant Pharmaceuticals International Inc at JPMorgan Healthcare Conference
Dec 16, 2015
Valeant Pharmaceuticals International Inc Investor Day
Nov 18, 2015
Valeant Pharmaceuticals International Inc at Jefferies Autumn Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 1.86% 11.04%
Operating margin 16.07% 23.11%
EBITD margin - 55.83%
Return on average assets 0.43% 3.36%
Return on average equity 3.11% 17.52%
Employees 16,800 -
CDP Score - -

Address

2150 Saint-Elzear Blvd W
LAVAL, QC H7L 4A8
Canada
+1-514-7446792 (Phone)
+1-514-7446272 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Company's developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Company's Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.

Officers and directors

Robert A. Ingram Interim Chairman of the Board
Age: 73
Bio & Compensation  - Reuters
Howard Bradley Schiller Interim Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Robert L. Rosiello Chief Financial Officer, Executive Vice President
Age: 57
Bio & Compensation  - Reuters
Pavel Mirovsky President and General Manager, Europe
Age: 64
Bio & Compensation  - Reuters
Robert Roswell Chai-Onn Executive Vice President, General Counsel and Chief Legal Officer, Head of Corporate and Business Development, Director
Age: 44
Bio & Compensation  - Reuters
Ari S. Kellen Executive Vice President, Company Group Chairman
Age: 51
Bio & Compensation  - Reuters
Laizer D. Kornwasser Executive Vice President, Company Group Chairman
Age: 44
Bio & Compensation  - Reuters
Brian M. Stolz Executive Vice President - Administration, Chief Human Capital Officer
Age: 39
Bio & Compensation  - Reuters
D. Robert Hale Director
Age: 30
Bio & Compensation  - Reuters
Ronald Harold Farmer Independent Director
Age: 64
Bio & Compensation  - Reuters